Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cre-encoding adenovirus (Ad-Cre) is a viral vector used primarily in research to achieve site-specific recombination in cells or tissues containing loxP-flanked (floxed) DNA sequences. It utilizes an adenoviral backbone (typically Ad5) to deliver the gene for Cre recombinase. Upon infection, the Cre protein is expressed and catalyzes the deletion, inversion, or translocation of DNA between two loxP sites. In the provided context, it was used to create a mouse model of tuberous sclerosis complex (TSC)-associated renal cell carcinoma by inducing the loss of the *Tsc1* gene in the kidney. This system is a cornerstone of conditional gene knockout technology, allowing researchers to study the function of specific genes in a spatially and temporally controlled manner.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cre-encoding adenovirus.